Repatha Sales Surge 37% to $953 Million as Amgen's Overlooked Cardiovascular Growth Driver Gains Momentum
核心洞察
Repatha delivered $953 million in second-quarter 2026 sales, a 37% year-over-year increase, according to Amgen CEO Robert A. Bradway.
U.S. new-to-brand prescriptions grew more than 50% year over year, split roughly evenly between cardiologists and primary-care physicians treating high-risk primary-prevention patients.
Jim Cramer described Repatha as a biweekly injection that reduces the risk of death by 20% in people at high risk for heart attack (搜索) or stroke (搜索).
Amgen's Repatha (evolocumab) has emerged as a key catalyst behind the company's 2026 rally, with second-quarter sales reaching $953 million—a 37% year-over-year increase—according to CEO Robert A. Bradway on the company's Q2 2026 earnings call held August 4. The drug's momentum has drawn fresh attention from market commentators, including Jim Cramer, who argued on his August 31 CNBC Stop Trading segment that Wall Street has largely overlooked Repatha's commercial potential.
"People are talking about the incredible movement in Amgen, which is up about 31% this year. And a lot of it has to do with a particular drug that people aren't talking about, which is Repatha," Cramer said. Amgen recently pushed to a new 52-week high of $447.03, with a market capitalization of roughly $233 billion.
Clinical Profile and Mechanism
Cramer described Repatha as "a shot that you take every other week, and what it does is reduce the risk of death by 20% in people who have high risk for a heart attack (搜索) or stroke (搜索)." He added that the drug "works against diabetes (搜索) and high cholesterol (搜索)."
Cramer also highlighted an evolving clinical practice pattern in which cardiologists are increasingly pushing LDL cholesterol as low as possible. In his view, this shift expands the pool of patients who could become candidates for intensified lipid-lowering therapy over time.
Commercial Momentum and Prescribing Trends
On the Q2 2026 earnings call, Bradway stated, "Starting with general medicine, Repatha delivered $953 million in second-quarter sales, growing 37% year over year." Management flagged that U.S. new-to-brand prescriptions are growing more than 50% year over year, split roughly evenly between expanded cardiologist use and adoption by primary-care physicians treating high-risk primary-prevention patients.
Repatha is one of six growth drivers that grew 26% in aggregate and represented nearly 70% of second-quarter product sales. Amgen raised full-year guidance to $38.2–$39.4 billion in revenue and non-GAAP EPS of $22.30 to $23.50.
Reimbursement Challenges
Despite the drug's clinical profile, Cramer paired his enthusiasm with a commercial caveat: "This Repatha is so revolutionary, but it was hard. You had to fight the insurance companies." He emphasized that efficacy and reimbursement are separate issues, and that payer resistance can gate the revenue ramp-up.
Market Context and Valuation
Cramer positioned Repatha as potentially the largest opportunity behind Eli Lilly's GLP-1 franchise, stating, "That's going to be the biggest market of all time, with the exception of what Eli Lilly has tapped into." On August 27, Cramer called Lilly "the trillion dollar drug company that I like so much."
Lilly carries a market cap around $1.05 trillion and trades at a forward P/E of 32, versus Amgen's forward P/E of 19. Lilly shares are up 9.83% year to date after a 6.44% pullback in the past week.
On August 31, Amgen published fresh cardiovascular data from the ESC Congress 2026 tied to Repatha's primary-prevention profile, the same day Cramer's segment aired. With quarterly sales approaching $1 billion and growing 37% annually, Repatha is becoming a meaningful growth engine for Amgen, and Cramer argues that investors may still be underestimating how large the cardiovascular opportunity can become.